| scholarly article | Q13442814 |
| P50 | author | Darell D. Bigner | Q57195229 |
| David A Reardon | Q73570385 | ||
| Nina A. Paleologos | Q121436715 | ||
| P2093 | author name string | John H Sampson | |
| Randy Jensen | |||
| Andrew Sloan | |||
| Maciej M Mrugala | |||
| Joachim M Baehring | |||
| Scott Cruickshank | |||
| Amy B Heimberger | |||
| Tibor Keler | |||
| Morris D Groves | |||
| Thomas A Davis | |||
| Gary E Archer | |||
| Rose K Lai | |||
| James Schuster | |||
| Lawrence D Recht | |||
| Jennifer A Green | |||
| P2860 | cites work | The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling | Q38349130 |
| EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms. | Q39314446 | ||
| Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors | Q40630013 | ||
| Response criteria for phase II studies of supratentorial malignant glioma | Q44781447 | ||
| Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. | Q55466614 | ||
| Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. | Q55471514 | ||
| IDH1 and IDH2 mutations in gliomas | Q24648948 | ||
| Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 | Q24651548 | ||
| Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme | Q27824801 | ||
| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 | ||
| Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma | Q33286242 | ||
| Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma | Q33610591 | ||
| Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma | Q34069375 | ||
| Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma | Q34488771 | ||
| Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma | Q34722415 | ||
| Microvesicles: messengers and mediators of tumor progression | Q34987500 | ||
| EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway | Q36510801 | ||
| P433 | issue | 6 | |
| P921 | main subject | glioblastoma | Q282142 |
| multicenter clinical trial | Q6934595 | ||
| phase II clinical trial | Q42824440 | ||
| P304 | page(s) | 854-61 | |
| P577 | publication date | 2015-06-01 | |
| P1433 | published in | Neuro-Oncology | Q15724471 |
| P1476 | title | A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study | |
| P478 | volume | 17 |
| Q37262109 | A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma |
| Q58122179 | A Critical Overview of Targeted Therapies for Glioblastoma |
| Q33913465 | A Phase II trial of tandutinib (MLN 518) in combination with bevacizumab for patients with recurrent glioblastoma |
| Q46093038 | A TNF-JNK-Axl-ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma. |
| Q55001435 | A pilot study of peptide vaccines for VEGF receptor 1 and 2 in patients with recurrent/progressive high grade glioma. |
| Q90452597 | A retrospective survival analysis of Glioblastoma patients treated with selective serotonin reuptake inhibitors |
| Q45946525 | A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. |
| Q88855717 | ACT IV: the final act for rindopepimut? |
| Q39045586 | Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities |
| Q37680966 | Advances in Immunotherapy for Glioblastoma Multiforme |
| Q39139224 | Advances in Molecular Imaging of Locally Delivered Targeted Therapeutics for Central Nervous System Tumors. |
| Q38777058 | Advances in the molecular genetics of gliomas - implications for classification and therapy |
| Q26773514 | Advances in the treatment of newly diagnosed glioblastoma |
| Q90215360 | An Innovative Immunotherapy Vaccine with Combination Checkpoint Blockade as a First Line Treatment for Glioblastoma in the Context of Current Treatments |
| Q93199833 | Anti-glioma effect of intracranial vaccination with tumor cell lysate plus flagellin in mice |
| Q94230437 | Anti‐epidermal growth factor receptor therapy for glioblastoma in adults |
| Q39243060 | Applied Cancer Immunogenomics: Leveraging Neoantigen Discovery in Glioblastoma |
| Q38625131 | BRAF inhibitors in BRAF-V600 mutated primary neuroepithelial brain tumors. |
| Q40246434 | Bevacizumab: Zankapfel der Glioblastomtherapie |
| Q49189846 | Beyond Alkylating Agents for Gliomas: Quo Vadimus? |
| Q90326760 | CD27 stimulation unveils the efficacy of linked class I/II peptide vaccines in poorly immunogenic tumors by orchestrating a coordinated CD4/CD8 T cell response |
| Q36893225 | CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients |
| Q27612411 | CIViC database |
| Q55259532 | CNS cancer immunity cycle and strategies to target this for glioblastoma. |
| Q38586617 | Circulating biomarkers for gliomas |
| Q90481791 | Combined-therapeutic strategies synergistically potentiate glioblastoma multiforme treatment via nanotechnology |
| Q38909071 | Concepts in glioma immunotherapy |
| Q47781482 | Contemporary management of high-grade gliomas. |
| Q60046462 | Current Options and Future Directions in Immune Therapy for Glioblastoma |
| Q52344613 | Current Strategies to Enhance Anti-Tumour Immunity. |
| Q28087306 | Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma |
| Q92570152 | Current and Future Trends on Diagnosis and Prognosis of Glioblastoma: From Molecular Biology to Proteomics |
| Q47878958 | Current and emerging EGFR therapies for glioblastoma. |
| Q50109459 | Current state and future prospects of immunotherapy for glioma |
| Q55457323 | Current state of immunotherapy for glioblastoma. |
| Q38780728 | Current status and future prospects of peptide-based cancer vaccines |
| Q59342675 | Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade |
| Q52365121 | Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach. |
| Q26778787 | Development of targeted therapies in treatment of glioblastoma |
| Q26752558 | Direct Delivery of Antigens to Dendritic Cells via Antibodies Specific for Endocytic Receptors as a Promising Strategy for Future Therapies |
| Q26853549 | EGFR Amplification and Glioblastoma Stem-Like Cells |
| Q39383476 | EGFR and EGFRvIII Promote Angiogenesis and Cell Invasion in Glioblastoma: Combination Therapies for an Effective Treatment |
| Q40089704 | EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise. |
| Q50069174 | EGFRvIII vaccine in glioblastoma-InACT-IVe or not ReACTive enough? |
| Q89848700 | EGFRvIII: An Oncogene with Ambiguous Role |
| Q48515806 | Efficacy of a ketogenic diet with concomitant intranasal perillyl alcohol as a novel strategy for the therapy of recurrent glioblastoma |
| Q37025105 | Emerging immunotherapies for glioblastoma |
| Q50100856 | Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies |
| Q64883724 | Fire in the Smoke: Battling Brain Tumors. |
| Q60547811 | From Molecular to Clinical Radiation Biology of Glioblastoma |
| Q60908457 | Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy |
| Q90926971 | Glioblastoma Therapy in the Age of Molecular Medicine |
| Q57111067 | Glioblastoma Treatments: An Account of Recent Industrial Developments |
| Q38516823 | Glioblastoma antigen discovery--foundations for immunotherapy. |
| Q28082603 | Glioblastoma multiforme: emerging treatments and stratification markers beyond new drugs |
| Q38597700 | Glioblastoma targeted therapy: updated approaches from recent biological insights |
| Q90442569 | HHLA2 is a novel prognostic predictor and potential therapeutic target in malignant glioma |
| Q54867398 | Hallmarks of glioblastoma: a systematic review. |
| Q26740664 | High-grade glioma management and response assessment-recent advances and current challenges |
| Q33721106 | Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies |
| Q33656811 | History and current state of immunotherapy in glioma and brain metastasis |
| Q38809194 | Human cytomegalovirus-based immunotherapy to treat glioblastoma: Into the future |
| Q33733266 | Icariside II induces cell cycle arrest and apoptosis in human glioblastoma cells through suppressing Akt activation and potentiating FOXO3a activity |
| Q38741186 | Identification of T cell target antigens in glioblastoma stem-like cells using an integrated proteomics-based approach in patient specimens |
| Q28069424 | Immune Responses to Epidermal Growth Factor Receptor (EGFR) and Their Application for Cancer Treatment |
| Q38659771 | Immunomonitoring in glioma immunotherapy: current status and future perspectives |
| Q38752191 | Immunotherapy and radiation in glioblastoma. |
| Q39016790 | Immunotherapy approaches in the treatment of malignant brain tumors |
| Q57475700 | Immunotherapy for Brain Tumors |
| Q91199920 | Immunotherapy for High Grade Gliomas: A Clinical Update and Practical Considerations for Neurosurgeons |
| Q26750765 | Immunotherapy for cancer in the central nervous system: Current and future directions |
| Q42396502 | Immunotherapy for glioblastoma: are we finally getting closer? |
| Q37050960 | Immunotherapy in glioblastoma: emerging options in precision medicine |
| Q28078539 | Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites? |
| Q64928237 | Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations. |
| Q38953024 | Improving vaccine efficacy against malignant glioma |
| Q38838354 | Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma |
| Q38832510 | Investigational new drugs for brain cancer |
| Q57147125 | Lessons learned from rindopepimut treatment in patients with EGFRvIII-expressing glioblastoma |
| Q39312420 | MRI in Glioma Immunotherapy: Evidence, Pitfalls, and Perspectives. |
| Q33728772 | MRI-Guided Stereotactic Biopsy of Murine GBM for Spatiotemporal Molecular Genomic Assessment |
| Q34552791 | Manipulation of Innate and Adaptive Immunity through Cancer Vaccines. |
| Q39965737 | Molecular Diagnostics of Gliomas Using Next Generation Sequencing of a Glioma-Tailored Gene Panel |
| Q37225334 | Multi-platform molecular profiling of a large cohort of glioblastomas reveals potential therapeutic strategies |
| Q38741932 | Neuro-oncology biotech industry progress report. |
| Q39043417 | Novel vaccines for glioblastoma: clinical update and perspective |
| Q26776345 | Overview of current immunotherapeutic strategies for glioma |
| Q36493843 | PD-L1 expression and prognostic impact in glioblastoma |
| Q38969029 | Peptides as a therapeutic avenue for nanocarrier-aided targeting of glioma |
| Q48822128 | Personalized medicine in neuro-oncology |
| Q41064782 | Perspectives on investigational drugs and immunotherapies for glioblastoma |
| Q38800041 | Pharmacotherapies for the treatment of glioblastoma - current evidence and perspectives |
| Q38912327 | Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma |
| Q92436994 | Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma |
| Q53370386 | Point/counterpoint: randomized versus single-arm phase II clinical trials for patients with newly diagnosed glioblastoma |
| Q37078999 | Prioritization schema for immunotherapy clinical trials in glioblastoma |
| Q38748694 | Prospect of rindopepimut in the treatment of glioblastoma. |
| Q28081371 | Prospects of immune checkpoint modulators in the treatment of glioblastoma |
| Q55457286 | Quo Vadis-Do Immunotherapies Have a Role in Glioblastoma? |
| Q91743219 | Rapid and ultrasensitive digital PCR (dPCR) profiling of EGFRvIII in tumor cells and tissues |
| Q60914597 | Recent Advances in Oncolytic Virotherapy and Immunotherapy for Glioblastoma: A Glimmer of Hope in the Search for an Effective Therapy? |
| Q38905187 | Recent Advances on the Molecular Pathology of Glial Neoplasms in Children and Adults |
| Q37239071 | Recent advances and future of immunotherapy for glioblastoma |
| Q58117045 | Receptor-Targeted Glial Brain Tumor Therapies |
| Q46600515 | Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial |
| Q39038768 | Selection of epitopes from self-antigens for eliciting Th2 or Th1 activity in the treatment of autoimmune disease or cancer |
| Q36558234 | Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy. |
| Q33746041 | Single vs. combination immunotherapeutic strategies for glioma. |
| Q64057061 | Strategies for developing and optimizing cancer vaccines |
| Q38738053 | Systemic therapies in the treatment of non-small-cell lung cancer brain metastases |
| Q90417081 | T-Cell based therapies for overcoming neuroanatomical and immunosuppressive challenges within the glioma microenvironment |
| Q50130464 | Targeting Neoantigens in Glioblastoma: An Overview of Cancer Immunogenomics and Translational Implications. |
| Q89700545 | Targeting cellular pathways in glioblastoma multiforme |
| Q39042442 | The Safety of available immunotherapy for the treatment of glioblastoma. |
| Q38743460 | The challenges associated with molecular targeted therapies for glioblastoma |
| Q37702586 | The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer |
| Q36493820 | The intersection of cancer, cancer stem cells, and the immune system: therapeutic opportunities |
| Q35994427 | The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy |
| Q58700123 | Therapeutic Immunization against Glioblastoma |
| Q38454659 | Toward precision medicine in glioblastoma: the promise and the challenges |
| Q42396516 | Tregs in gliomas - the jury is still out. |
| Q90211010 | Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis |
| Q39228039 | Tumor Vaccines for Malignant Gliomas |
| Q47583155 | Vaccination in the immunotherapy of glioblastoma |
| Q52623832 | Vaccine Strategies in Gliomas |
| Q57160349 | Vaccine-Based Immunotherapeutics for the Treatment of Glioblastoma: Advances, Challenges, and Future Perspectives |
| Q38789860 | Vaccine-based immunotherapeutic approaches to gliomas and beyond |
| Q26796314 | Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges |
| Q28086839 | What next for newly diagnosed glioblastoma? |
| Q52672321 | Working plan for the use of patient-reported outcome measures in adults with brain tumours: a Response Assessment in Neuro-Oncology (RANO) initiative |
| Q55460052 | [Treatment of the glioma microenvironment]. |
Search more.